SCHEMBL6138864

SCHEMBL6138864

COCCOCCOC(=O)CCCCC(=O)c1ccc(C#Cc2ccc(SC)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.38
ABCB11 O95342 1/20 0.36
CYP3A4 P08684 1/20 0.36
ADRA2B P18089 1/20 0.36
OPRD1 P41143 1/20 0.36
SCN5A Q14524 1/20 0.36
MAPT P10636 1/20 0.36
CTNNB1 P35222 1/20 0.35
ACACB O00763 2/20 0.35
KDR P35968 4/20 0.34
NPC1 O15118 1/20 0.34
HRH2 P25021 3/20 0.34
HRH1 P35367 3/20 0.34
HAO1 Q9UJM8 1/20 0.34
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6138941 0.90 HAO1 (0.44) L3MBTL1ABCB11CYP3A4ADRA2BOPRD1
SCHEMBL11650221 0.83 PLK1 (0.41) L3MBTL1MAPTCTNNB1NPC1HAO1
Ethylene SCHEMBL11651022 0.81 HAO1 (0.40) L3MBTL1MAPTCTNNB1NPC1HAO1
SCHEMBL6138900 0.80 HDAC1 (0.49) L3MBTL1ABCB11CYP3A4ADRA2BOPRD1
SCHEMBL6138868 0.79 CTNNB1 (0.34) L3MBTL1ABCB11CYP3A4ADRA2BOPRD1
SCHEMBL11657015 0.78 PLK1 (0.46) L3MBTL1MAPTNPC1HAO1MMP2
SCHEMBL751866 0.74 CYP3A4 (0.56) ABCB11CYP3A4ADRA2BOPRD1SCN5A
SCHEMBL6138736 0.72 HAO1 (0.56) L3MBTL1NPC1HAO1MMP2MMP9
SCHEMBL7196791 0.72 L3MBTL1 (0.55) L3MBTL1MAPTNPC1HAO1MMP2
SCHEMBL2304415 0.71 DGKA (0.57) ABCB11CYP3A4ADRA2BOPRD1SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1215203-B1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2005-02-16 EP disclosed
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-10-28 US disclosed
US-6770644-B1 Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient ONO PHARMACEUTICALS CO., LTD. (JP) 2004-08-03 US disclosed
EP-1215203-A1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient HIF1AN, IL6, PYGM L3MBTL1 1777/4885ABCB11 3773/4885CYP3A4 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.